Flaxseed Lignan Complex Administration in Older Human Type 2 Diabetics Manages Central Obesity and Prothrombosis – An Invitation to Further Investigation into Polypharmacy Reduction
Flaxseed Lignan Complex Administration in Older Human Type 2 Diabetics Manages Central Obesity and Prothrombosis – An Invitation to Further Investigation into Polypharmacy Reduction
Year: 2012
Authors: Barre, D.E. Mizier-Barre, K.A. Stelmach, E. Hobson, J. Griscti, O. Rudiuk, A. Muthuthevar, D.
Publication Name: J. Nutr. & Metab.
Publication Details: Volume 2012; doi:10.1155
Abstract:
consumers and did not change from 2.7 mG/L in the placebo group. IL-6 levels dropped from 4.1 to 3.6 pG/mL while the IL-6 measured at 4.3 pG/mL initially in the placebo group ended at 5.4 pG/mL. TNF-alpha was consistent at 1.1 pG/mL across the board in the FLC and placebo groups. Univariate analysis revealed that both blood glucose and A1c fell significantly as the result of FLC administration compared to placebo. In terms of systolic and diastolic blood pressures, FLC and placebo both showed a downward trend from their introduction to finish of application. A greater numbers of subjects with elevated diastolic pressures in a future study might yield a statistically significant drop in that pressure in type 2 diabetics. FLC caused a significant reduction in inflammation as measured by reductions in CRP and the main modulator of CRP formation, IL-6 when only univariate analysis was used. This was the first study to show that at doses higher than 300 mg SDG/day it is the IL-6 and not the TNF-alpha modulating the blood plasma glucose concentration reduction in type 2 diabetics as a result of FLC consumption. It is concluded that this FLC given at a dose of 600 mg SDG/day for three months combats in a statistically significant fashion, in this study population, waist circumference (central obesity) gain, and the prothrombotic state and hence potentially the risk of myocardial infarction and stroke. It is important to note that these changes took place despite the consistent consumption of various medications concurrently used to combat these issues. However, in addition, much larger numbers of subjects may reveal decreases in glucose and A1c, CRP, and IL-6 levels using the same protocol with adjustments for multiple comparisons. It is also concluded that this FLC dose for the three-month timeframe in this population does not impact the blood pressure or TC : HDL-c ratio or any of its lipid/lipoprotein contributors to that ratio. A more definitive answer to the question as to whether this unique FLC will match or exceed the benefits of reduced vascular complications resulting from polypharmacy used to address the unique combination of hyperglycaemia, waist circumference, prothrombotic state, and inflammation remains to be determined from a much larger multicentre, longer term trial planned by this laboratory using the same protocol. It is particularly intriguing that FLC appears to have the potential to reduce the inflammation contributing to plaque rupture and hence the prothrombotic tendency, the last chance to stop the cascade before myocardial infarction or stroke, all apparently with minimal side effects or other complications. (Editors comments)
